Proinsulin-specific B-cell receptor (Proinsulin-specific BCR)

Proinsulin-specific B-cell receptors (BCRs) are specialized surface immunoglobulins that play a pivotal role in the autoimmune cascade leading to Type 1 Diabetes (T1D). These receptors allow autoreactive B cells to selectively bind, internalize, and present proinsulin-derived peptides to pathogenic T cells, acting as essential antigen-presenting cells (APCs) in the pancreatic environment (Smith et al., 2017, PubMed: 28416514). This interaction is critical for the activation and expansion of T cells that ultimately destroy insulin-producing beta cells. Because these BCRs are unique to the pathogenic B-cell clones, they represent an ideal target for antigen-specific therapies designed to eliminate or silence the autoimmune response without inducing broad immunosuppression. Clinical trials with pan-B-cell depleting agents like Rituximab have validated the importance of the B-cell compartment in T1D, but the focus is shifting toward more specific interventions (Thomas et al., 2019, PubMed: 31213546). Emerging strategies include the use of proinsulin-conjugated nanoparticles or inverse vaccines that leverage the BCR's specificity to deliver tolerogenic signals or cytotoxic payloads directly to the autoreactive cells. Successfully targeting these receptors could provide a disease-modifying treatment that preserves endogenous insulin production while maintaining overall immune competence.

Other names

Insulin-specific B-cell receptorProinsulin-reactive B-cell receptorAutoreactive B-cell receptor

Depletion of autoreactive B cells or inhibition of their antigen-presenting function to prevent T-cell mediated destruction of pancreatic beta cells.